RSV Immunization Study: Nirsevimab for Infants

We are studying how the nirsevimab immunization affects infants' immune responses to RSV infections. This research aims to understand the role of age, weight, and maternal antibodies in developing immunity.

1-2 years≤5 visitsMonitoring phase (IV)No PlaceboStandard MedicinesInjectionInfectious DiseasesPulmonology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Beyfortus
Beyfortus is a medicine given to babies to help prevent serious lung infections caused by a common respiratory virus.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Nirsevimab
Nirsevimab is a long-acting antibody that helps prevent severe respiratory syncytial virus (RSV) infection in infants and young children.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Rijksinstituut voor Volksgezondheid en Milieu (RIVM)
KIM
De Bilt, Netherlands
Sponsor: Rijksinstituut voor Volksgezondheid en Milieu (RIVM)
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.